Tuning the potency and selectivity of ImmTAC molecules by affinity modulation
Clinical and Experimental Immunology · 2024
DOI: 10.1093/cei/uxad120 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Immunology, 2024. Verfasst von Ian B Robertson und 10 weiteren Autor:innen. Beteiligte Einrichtung: Immunocore Limited, Drug Discovery and Protein Engineering, Abingdon, Oxon, UK. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Neoplasms. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Immunocore Ltd.
Abstract (Originalsprache)
T-cell-engaging bispecifics have great clinical potential for the treatment of cancer and infectious diseases. The binding affinity and kinetics of a bispecific molecule for both target and T-cell CD3 have substantial effects on potency and specificity, but the rules governing these relationships are not fully understood. Using immune mobilizing monoclonal TCRs against cancer (ImmTAC) molecules as a model, we explored the impact of altering affinity for target and CD3 on the potency and specificity of the redirected T-cell response. This class of bispecifics binds specific target peptides presented by human leukocyte antigen on the cell surface via an affinity-enhanced T-cell receptor and can redirect T-cell activation with an anti-CD3 effector moiety. The data reveal that combining a strong affinity TCR with an intermediate affinity anti-CD3 results in optimal T-cell activation, while strong affinity of both targeting and effector domains significantly reduces maximum cytokine release. Moreover, by optimizing the affinity of both parts of the molecule, it is possible to improve the selectivity. These results could be effectively modelled based on kinetic proofreading with limited signalling. This model explained the experimental observation that strong binding at both ends of the molecules leads to reduced activity, through very stable target-bispecific-effector complexes leading to CD3 entering a non-signalling dark state. These findings have important implications for the design of anti-CD3-based bispecifics with optimal biophysical parameters for both activity and specificity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Immunocore Limited, Drug Discovery and Protein Engineering, Abingdon, Oxon, UK.
- Sir William Dunn School of Pathology, University of Oxford, Oxford, UK.
ORCID-Profile: Ian B Robertson, Stephen Harper
Förderung
- Immunocore Ltd
Zitieren
APA
Robertson, I. B., Mulvaney, R., Dieckmann, N., Vantellini, A., Canestraro, M., Amicarella, F., O'Dwyer, R., Cole, D. K., Harper, S., Dushek, O., & Kirk, P. (2024). Tuning the potency and selectivity of ImmTAC molecules by affinity modulation. Clinical and Experimental Immunology. https://doi.org/10.1093/cei/uxad120
Vancouver
Robertson IB, Mulvaney R, Dieckmann N, Vantellini A, Canestraro M, Amicarella F, et al. Tuning the potency and selectivity of ImmTAC molecules by affinity modulation. Clinical and Experimental Immunology. 2024. doi:10.1093/cei/uxad120
BibTeX
@article{Robertson2024,
author = {Robertson, Ian B and Mulvaney, Rachel and Dieckmann, Nele and Vantellini, Alessio and Canestraro, Martina and Amicarella, Francesca and O'Dwyer, Ronan and Cole, David K and Harper, Stephen and Dushek, Omer and Kirk, Peter},
title = {Tuning the potency and selectivity of ImmTAC molecules by affinity modulation},
journal = {Clinical and Experimental Immunology},
year = {2024},
doi = {10.1093/cei/uxad120}
}
EUVIMED